Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Reiss

Showing results (351-360 of 509) with videos related to

Pageof 51
Sort By:
The Journal of Clinical Endocrinology and Metabolism|July 9, 2004
Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patientsMarc van der Valk, Gideon Allick, Gerrit Jan Weverling, et al.
AIDS (London, England)|August 7, 2019
Serious clinical events in HIV-positive persons with chronic kidney diseaseLene Ryom, Jens D Lundgren, Matthew Law, et al.
Open Forum Infectious Diseases|July 7, 2017
High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal FluidThijs Booiman, Ferdinand W Wit, Irma Maurer, et al.
Antiviral Therapy|November 21, 2007
Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patientsManon van der Lee, Raaj Sankatsing, Emile Schippers, et al.
Plos One|January 29, 2019
Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trialJose I Bernardino, Amanda Mocroft, Cedrick Wallet, et al.
AIDS (London, England)|March 8, 2016
Improvements over time in short-term mortality following myocardial infarction in HIV-positive individualsCamilla Ingrid Hatleberg, Lene Ryom, Wafaa El-Sadr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 18, 2018
Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D: A: D Cohort AnalysisAmit C Achhra, Caroline Sabin, Lene Ryom, et al.
AIDS (London, England)|April 20, 2002
Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohortJeanne P Dieleman, Marielle Jambroes, Inge C Gyssens, et al.
AIDS (London, England)|May 6, 2016
White matter hyperintensities in relation to cognition in HIV-infected men with sustained suppressed viral load on combination antiretroviral therapyTanja Su, Ferdinand W N M Wit, Matthan W A Caan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 22, 2020
Effect of Changes in Body Mass Index on the Risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive Individuals: Results From the D:A:D StudyKathy Petoumenos, Locadiah Kuwanda, Lene Ryom, et al.
Pageof 51

Showing results (351-360 of 509) with videos related to

Sort By:
Pageof 51
The Journal of Clinical Endocrinology and Metabolism|July 9, 2004
Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patientsMarc van der Valk, Gideon Allick, Gerrit Jan Weverling, et al.
AIDS (London, England)|August 7, 2019
Serious clinical events in HIV-positive persons with chronic kidney diseaseLene Ryom, Jens D Lundgren, Matthew Law, et al.
Open Forum Infectious Diseases|July 7, 2017
High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal FluidThijs Booiman, Ferdinand W Wit, Irma Maurer, et al.
Antiviral Therapy|November 21, 2007
Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patientsManon van der Lee, Raaj Sankatsing, Emile Schippers, et al.
Plos One|January 29, 2019
Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trialJose I Bernardino, Amanda Mocroft, Cedrick Wallet, et al.
AIDS (London, England)|March 8, 2016
Improvements over time in short-term mortality following myocardial infarction in HIV-positive individualsCamilla Ingrid Hatleberg, Lene Ryom, Wafaa El-Sadr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 18, 2018
Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D: A: D Cohort AnalysisAmit C Achhra, Caroline Sabin, Lene Ryom, et al.
AIDS (London, England)|April 20, 2002
Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohortJeanne P Dieleman, Marielle Jambroes, Inge C Gyssens, et al.
AIDS (London, England)|May 6, 2016
White matter hyperintensities in relation to cognition in HIV-infected men with sustained suppressed viral load on combination antiretroviral therapyTanja Su, Ferdinand W N M Wit, Matthan W A Caan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 22, 2020
Effect of Changes in Body Mass Index on the Risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive Individuals: Results From the D:A:D StudyKathy Petoumenos, Locadiah Kuwanda, Lene Ryom, et al.
Pageof 51